Haemonetics (HAE) Tops Q4 EPS by 6c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $118.51 +2.02%
EPS Growth %: +1.6%
Financial Fact:
Cost of goods sold: 116.01M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: +1.6%
Financial Fact:
Cost of goods sold: 116.01M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q4 EPS of $0.65, $0.06 better than the analyst estimate of $0.59. Revenue for the quarter came in at $265 million versus the consensus estimate of $257.82 million.
GUIDANCE:
Haemonetics sees FY2023 EPS of $2.50-$2.90, versus the consensus of $2.53.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- SLM (SLM) Misses Q3 EPS by 36c; lowers guidance
- RBC Capital Reiterates Outperform Rating on Verisk Analytics (VRSK)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
